Product information
| Catalog No. | Product Name | Species Reactivity |
|---|
| GM-Tg-hg-T87075-Ab-1/ GM-Tg-hg-T87075-Ab-2 | Anti-Human CD3E monoclonal antibody | Human |
| GM-Tg-rg-T87075-Ab-1/ GM-Tg-rg-T87075-Ab-2 | Anti-Rat CD3E monoclonal antibody | Rat |
| GM-Tg-mg-T87075-Ab-1/ GM-Tg-mg-T87075-Ab-2 | Anti-Mouse CD3E monoclonal antibody | Mouse |
| GM-Tg-cynog-T87075-Ab-1/ GM-Tg-cynog-T87075-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CD3E monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T87075-Ab-1/ GM-Tg-felg-T87075-Ab-2 | Anti-Feline CD3E monoclonal antibody | Feline |
| GM-Tg-cang-T87075-Ab-1/ GM-Tg-cang-T87075-Ab-2 | Anti-Canine CD3E monoclonal antibody | Canine |
| GM-Tg-bovg-T87075-Ab-1/ GM-Tg-bovg-T87075-Ab-2 | Anti-Bovine CD3E monoclonal antibody | Bovine |
| GM-Tg-equg-T87075-Ab-1/ GM-Tg-equg-T87075-Ab-2 | Anti-Equine CD3E monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T87075-Ab-1/ GM-Tg-hg-T87075-Ab-2; GM-Tg-rg-T87075-Ab-1/ GM-Tg-rg-T87075-Ab-2;
GM-Tg-mg-T87075-Ab-1/ GM-Tg-mg-T87075-Ab-2; GM-Tg-cynog-T87075-Ab-1/ GM-Tg-cynog-T87075-Ab-2;
GM-Tg-felg-T87075-Ab-1/ GM-Tg-felg-T87075-Ab-2; GM-Tg-cang-T87075-Ab-1/ GM-Tg-cang-T87075-Ab-2;
GM-Tg-bovg-T87075-Ab-1/ GM-Tg-bovg-T87075-Ab-2; GM-Tg-equg-T87075-Ab-1/ GM-Tg-equg-T87075-Ab-2 |
| Products Name | Anti-CD3E monoclonal antibody |
| Format | mab |
| Target Name | CD3E |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
| Derivation (species) | Mouse |
CH1+2+3 Isotype
(Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-CD3E benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation | Lyophilized from sterile PBS, PH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Biosimilar | GMP-Bios-ab-356 | Pre-Made Mosunetuzumab biosimilar, Bispecific mAb, Anti-CD3E;MS4A1/CD20 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody |
| Biosimilar | GMP-Bios-INN-790 | Pre-Made Dafsolimab Setaritox Biosimilar, Whole Mab Adc, Anti-Cd3E Antibody: Anti-CD3epsilon/IMD18/T3E/TCRE therapeutic antibody Drug Conjugate |
| Biosimilar | GMP-Bios-ab-546 | Pre-Made Talquetamab biosimilar, Bispecific mAb, Anti-GPRC5D;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
| Biosimilar | GMP-Bios-ab-622 | Pre-Made Visilizumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
| Biosimilar | GMP-Bios-ab-386 | Pre-Made Obrindatamab biosimilar, Bispecific scFv with Domain Crossover, Anti-CD276;CD3E Antibody: Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2;T3E/TCRE/IMD18 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-104 | Pre-Made Cibisatamab biosimilar, Bispecific mAb with Domain Crossover: Anti-CEACAM5;CD3E therapeutic antibody |
| Biosimilar | GMP-Bios-ab-391 | Pre-Made Odronextamab biosimilar, Bispecific mAb, Anti-MS4A1/CD20;CD3E Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7;T3E/TCRE/IMD18 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-500 | Pre-Made Runimotamab biosimilar, Bispecific mAb, Anti-ERBB2/HER2;CD3E Antibody: Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;T3E/TCRE/IMD18 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-248 | Pre-Made Glofitamab biosimilar, Bispecific mAb with Domain Crossover, Anti-CD3E;MS4A1/CD20 antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7therapeutic antibody |
| Biosimilar | GMP-Bios-ab-705 | Pre-Made Ubamatamab biosimilar, Whole mAb, Anti-MUC16;CD3E Antibody: Anti-CA125;T3E/TCRE/IMD18 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-197 | Pre-Made Etevritamab biosimilar, Bispecific scFv, Anti-EGFR;CD3E Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;T3E/TCRE/IMD18 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-663 | Pre-Made Elranatamab biosimilar, Whole mAb, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-708 | Pre-Made Vepsitamab biosimilar, Whole mAb, Anti-MUC17;CD3E Antibody: Anti-MUC-17/MUC-3/MUC3;T3E/TCRE/IMD18 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-446 | Pre-Made Plamotamab biosimilar, Bispecific Mixed mAb and scFv, Anti-MS4A1/CD20;CD3E Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7;T3E/TCRE/IMD18 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-176 | Pre-Made Emerfetamab biosimilar, Bispecific scFv, Anti-CD33;CD3E Antibody: Anti-p67/SIGLEC3/SIGLEC-3;T3E/TCRE/IMD18 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-414 | Pre-Made Otelixizumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
| Biosimilar | GMP-Bios-ab-562 | Pre-Made Teplizumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
| Biosimilar | GMP-Bios-ab-433 | Pre-Made Pavurutamab biosimilar, Bispecific scFv, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-709 | Pre-Made Voxalatamab biosimilar, Whole mAb, Anti-FOLH1/GCPII;CD3E Antibody: Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-570 | Pre-Made Tidutamab biosimilar, Bispecific Mixed mAb and scFv, Anti-SSTR2;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
| Biosimilar | GMP-Bios-ab-619 | Pre-Made Vibecotamab biosimilar, Bispecific Mixed mAb and scFv, Anti-IL3RA;CD3E Antibody: Anti-CD123/IL3RX/IL3RY/IL3RAY/hIL-3Ra;T3E/TCRE/IMD18 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-624 | Pre-Made Vixtimotamab biosimilar, Bispecific Homodimer (VK-VH-VL'-VH', Tandem diabody)), Anti-CD3E;CD33 Antibody: Anti-T3E/TCRE/IMD18;p67/SIGLEC3/SIGLEC-3 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-189 | Pre-Made Epcoritamab biosimilar, Bispecific mAb, Anti-CD3E;MS4A1/CD20 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-006 | Pre-Made Acapatamab biosimilar, Bispecific scFv, Anti-FOLH1/GCPII;CD3E Antibody: Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-074 | Pre-Made Blinatumomab biosimilar, Bispecific T-Cell Engager, Anti-CD19;CD3E Antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-650 | Pre-Made Zolimomab biosimilar, Whole mAb, Anti-CD5 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
| Biosimilar | GMP-Bios-ab-670 | Pre-Made Gresonitamab biosimilar, Whole mAb, Anti-CLDN18;CD3E Antibody: Anti-SFTA5/SFTPJ;T3E/TCRE/IMD18 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-421 | Pre-Made Pacanalotamab biosimilar, Bispecific scFv, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-429 | Pre-Made Pasotuxizumab biosimilar, Bispecific scFv, Anti-FOLH1/GCPII;CD3E Antibody: Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-130 | Pre-Made Dafsolimab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
| Biosimilar | GMP-Bios-INN-772 | Pre-Made Catumaxomab Biosimilar, Bispecific, Anti-Cd3E; Epcam Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody |
| Biosimilar | GMP-Bios-INN-921 | Pre-Made Muromonab-Cd3 3Iosimilar, Whole Mab, Anti-Cd3E Antibody: Anti-CD3epsilon/IMD18/T3E/TCRE therapeutic antibody |
| Biosimilar | GMP-Bios-ab-360 | Pre-Made Muromonab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
| Biosimilar | GMP-Bios-ab-218 | Pre-Made Flotetuzumab biosimilar, Bispecific scFv with Crossover, Anti-IL3RA;CD3E Antibody: Anti-CD123/IL3RX/IL3RY/IL3RAY/hIL-3Ra;T3E/TCRE/IMD18 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-173 | Pre-Made Eluvixtamab biosimilar, Bispecific scFv, Anti-CD33;CD3E Antibody: Anti-p67/SIGLEC3/SIGLEC-3;T3E/TCRE/IMD18 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-552 | Pre-Made Tarlatamab biosimilar, Bispecific scFv, Anti-DLL3;CD3E Antibody: Anti-SCDO1;T3E/TCRE/IMD18 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-563 | Pre-Made Tepoditamab biosimilar, Bispecific mAb, Anti-CLEC12A/CD371;CD3E Antibody: Anti-CLL-1/CLL1/DCAL-2/MICL;T3E/TCRE/IMD18 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-380 | Pre-Made Nivatrotamab biosimilar, Bispecific Mixed mAb and scFv, Anti-GD2;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
| Biosimilar | GMP-Bios-ab-018 | Pre-Made Alnuctamab biosimilar, Bispecific mAb with Domain Crossover, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-528 | Pre-Made Solitomab biosimilar, Bispecific scFv, Anti-EPCAM;CD3E Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1;T3E/TCRE/IMD18 therapeutic antibody |
| Biosimilar | GMP-Bios-INN-845 | Pre-Made Ertumaxomab Biosimilar, Bispecific, Anti-Cd3E;Erbb2 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-557 | Pre-Made Teclistamab biosimilar, Bispecific mAb, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-220 | Pre-Made Foralumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
| Biosimilar | GMP-Bios-ab-555 | Pre-Made Tebentafusp biosimilar, scFv Fusion, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
| Biosimilar | GMP-Bios-ab-161 | Pre-Made Duvortuxizumab biosimilar, Bispecific scFv with Crossover, Anti-CD19;CD3E antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibody |
| Target Antigen | Products Developing | Multi-species CD3E/ IMD18/ T3E VLP (virus-like particle) (Products Developing) |
| ORF Viral Vector | pGMAP000214 | Human CD3E Adenovirus plasmid |
| ORF Viral Vector | vGMAP000214 | Human CD3E Adenovirus particle |
| ORF Viral Vector | pGMLPm000541 | mouse Cd3e Lentivirus plasmid |
| ORF Viral Vector | vGMLPm000541 | mouse Cd3e Lentivirus particle |
Target information
| Target ID | GM-T87075 |
| Target Name | CD3E |
| Gene ID | 916,12501,315609,699467,442981,493936,281054,100629532 |
| Gene Symbol and Synonyms | CD3,CD3E,CD3epsilon,IMD18,T3E,TCRE |
| Uniprot Accession | P07766,P27597,Q5R1Q1,Q28073 |
| Uniprot Entry Name | CD3E_HUMAN,CD3E_FELCA,CD3E_CANLF,CD3E_BOVIN |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target, Immuno-oncology Target, INN Index |
| Disease | N/A |
| Gene Ensembl | ENSG00000198851 |
| Target Classification | Checkpoint-Immuno Oncology |
The target: CD3E, gene name: CD3E, also named as IMD18, T3E, TCRE. The protein encoded by this gene is the CD3-epsilon polypeptide, which together with CD3-gamma, -delta and -zeta, and the T-cell receptor alpha/beta and gamma/delta heterodimers, forms the T-cell receptor-CD3 complex. This complex plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. The genes encoding the epsilon, gamma and delta polypeptides are located in the same cluster on chromosome 11. The epsilon polypeptide plays an essential role in T-cell development. Defects in this gene cause immunodeficiency. This gene has also been linked to a susceptibility to type I diabetes in women. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Go to CD3E/CD3E products collection >>
MSDS
Facebook
LinkedIn
Twitter
